Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Nintedanib Deployment in COVID-19 Interstitial Lung Disease

NCT04619680 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT04619680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04619680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Nintedanib Deployment in COVID-19 Interstitial Lung Disease
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 4
Overall status
Completed
Start date
November 18, 2020
Completion date
March 2, 2024
Enrollment
103 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, pulmonary fibrosis, respiratory disease